Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 8/20 | 0.50 |
| ▸ | HTR2A | P28223 | 8/20 | 0.50 |
| ▸ | HTR2B | P41595 | 6/20 | 0.50 |
| ▸ | ERN1 | O75460 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.36 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.36 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.36 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30665872 | 0.93 | HTR2A (0.50) | HTR2CHTR2AHTR2BERN1MEN1 | |
| SCHEMBL26654718 | 0.93 | HTR2A (0.50) | HTR2CHTR2AHTR2BERN1MEN1 | |
| SCHEMBL10459592 | 0.82 | HTR2A (0.34) | HTR2CHTR2AHTR2BERN1CYP3A4 | |
| SCHEMBL38652858 | 0.81 | HTR2A (0.42) | HTR2CHTR2AHTR2BCYP3A4MAPT | |
| SCHEMBL27033010 | 0.81 | MEN1 (0.47) | HTR2CHTR2AHTR2BMAPTMEN1 | |
| SCHEMBL29828820 | 0.81 | MEN1 (0.47) | HTR2CHTR2AHTR2BMAPTMEN1 | |
| SCHEMBL8637498 | 0.79 | POLB (0.41) | HTR2CHTR2AHTR2BERN1CYP3A4 | |
| SCHEMBL9086137 | 0.79 | ERN1 (0.46) | HTR2AERN1 | |
| SCHEMBL1701459 | 0.78 | AHR (0.42) | ERN1MAPTNPC1RAB9A | |
| SCHEMBL23363326 | 0.78 | MAOB (0.45) | HTR2CHTR2AHTR2BCYP3A4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250145637-A1 | SULFONAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) | 2025-05-08 | — | — | US | disclosed |
| EP-4385989-A1 | SULFONAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2024-06-19 | — | — | EP | disclosed |
| CN-117597341-A | Sulfonamide derivative, preparation method and application thereof in medicine | 江苏恒瑞医药股份有限公司 | 2024-02-23 | — | — | CN | disclosed |
| WO-2023016484-A1 | SULFONAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 江苏恒瑞医药股份有限公司 | 2023-02-16 | — | — | WO | disclosed |
| WO-2023016484-A1 | SULFONAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 江苏恒瑞医药股份有限公司 | 2023-02-16 | — | — | WO | disclosed |
| EP-0841925-B1 | ENDOTHELIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2006-10-04 | — | — | EP | disclosed |
| US-6482956-B2 | FOR THERAPY OF CARDIOVASCULAR, CEREBROVASCULAR, RESPIRATORY AND RENAL DISORDERS | SMITHKLINE BEECHAM CORPORATION | 2002-11-19 | — | — | US | disclosed |
| US-20020072614-A1 | Endothelin receptor antagonists | LUENGO JUAN IGNACIO (US) | 2002-06-13 | — | — | US | disclosed |
| US-6353116-B1 | Endothelin receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2002-03-05 | — | — | US | disclosed |
| EP-0841925-A4 | ENDOTHELIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2001-10-17 | — | — | EP | disclosed |
| US-6096897-A | NOVEL 1,2,3-TRIAZOLES | SMITHKLINE BEECHAM CORPORATION (US) | 2000-08-01 | — | — | US | disclosed |
| US-5969151-A | PYRAZOLE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-10-19 | — | — | US | disclosed |
| US-5958968-A | CARDIOVASCULAR DISORDERS; KIDNEY DIEASES | SMITHKLINE BEECHAM CORPORATION (US) | 1999-09-28 | — | — | US | disclosed |
| EP-0841925-A1 | ENDOTHELIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-05-20 | — | — | EP | disclosed |
| WO-1997004772-A1 | ENDOTHELIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250145637-A1 | SULFONAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | SULT2A1, KAT8, TST | HTR2C 4501/4885HTR2A 4514/4885HTR2B 4354/4885 |
| US-20020072614-A1 | Endothelin receptor antagonists | EDNRA, EDNRB, ECE1 | HTR2C 262/4885HTR2A 306/4885HTR2B 213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.